Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL234264 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL502964 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL2680343 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL2680240 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL476072 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL3971104 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL475859 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL502670 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090801 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA | |
| SCHEMBL17090772 | 1.00 | TSHR (0.53) | TSHRTHRBDNM1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-08-04 | — | — | US | disclosed |
| EP-2921499-B1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACIDS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-01-22 | — | — | EP | disclosed |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-11-05 | — | — | US | disclosed |
| EP-2921499-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | Takeda Pharmaceutical Company Limited (JP) | 2015-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315229-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | POLM, POLRMT, RNMT | TSHR 495/4885THRB 936/4885DNM1 1776/4885 |
| US-20190135852-A1 | METHOD FOR LIQUID-PHASE SYNTHESIS OF NUCLEIC ACID | RNGTT, POLR2H, POLR2E | TSHR 551/4885THRB 1506/4885DNM1 2698/4885 |
| US-10730904-B2 | Method for liquid-phase synthesis of nucleic acid | RNGTT, POLR2H, POLR2E | TSHR 411/4885THRB 1249/4885DNM1 1968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.